Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?

被引：22

作者：

Janikova, Andrea ^{[1
,2
]}

Bortlicek, Zbynek ^{[3
,4
]}

Campr, Vit ^{[5
,6
]}

Kopalova, Natasa ^{[1
,2
]}

Benesova, Katerina ^{[7
]}

Belada, David ^{[8
]}

Prochazka, Vit ^{[9
]}

Pytlik, Robert ^{[7
]}

Vokurka, Samuel ^{[10
,11
]}

Pirnos, Jan ^{[12
]}

Duras, Juraj ^{[13
]}

Mocikova, Heidi ^{[14
]}

Mayer, Jiri ^{[1
,2
]}

Trneny, Marek ^{[7
]}

机构：

[1] Masaryk Univ, Dept Internal Med Hematol & Oncol, Jihlavska 20, Brno 62500, Czech Republic

[2] Univ Hosp Brno, Brno 62500, Czech Republic

[3] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno 62500, Czech Republic

[4] Masaryk Univ, Fac Sci, Brno 62500, Czech Republic

[5] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic

[6] Fac Hosp Motol, Prague, Czech Republic

[7] Charles Univ Prague, Gen Hosp, Dept Med 1, Prague, Czech Republic

[8] Univ Hosp Hradec Kralove, Dept Clin Hematol, Hradec Kralove, Czech Republic

[9] Univ Hosp Olomouc, Dept Hematol, Olomouc, Czech Republic

[10] Charles Univ Prague, Dept Hematooncol, Plzen, Czech Republic

[11] Univ Hosp Plzen, Plzen, Czech Republic

[12] Hosp Ceske Budejovice, Dept Oncol, Ceske Budejovice, Czech Republic

[13] Teaching Hosp Ostrava, Dept Clin Hematol, Ostrava, Czech Republic

[14] Univ Hosp Kralovske Vinohrady, Dept Hematol, Prague, Czech Republic

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 08期

关键词：

Follicular lymphoma; rituximab; radiotherapy; NON-HODGKINS-LYMPHOMA; TERM-FOLLOW-UP; POSITRON-EMISSION-TOMOGRAPHY; INVOLVED FIELD RADIOTHERAPY; LOW-GRADE; RADIATION-THERAPY; CELLS; MANAGEMENT; TRANSLOCATION; SURVIVAL;

D O I：

10.3109/10428194.2014.990010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Early-stage follicular lymphoma (FL) has traditionally been treated with involved-field radiotherapy (RT). Rituximab (R) is a low-toxic, efficient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectively analyzed 93 patients with stage I-II indolent FL treated with RT (n = 65) or RT + R (n = 14) or R alone (n = 14). Median follow-up was 5.0 years for patients with RT, 2.8 years for the RT + R subgroup and 2.5 years for patients treated with R. The complete response rate was 92%, 100% and 86% (not significant) and the median PFS was 3.3 years, not reached and 4.9 years (p = 0.035) for the RT, RT + R and R arms, with no impact on overall survival. R combined with RT seems to give better results in terms of global FL control, but longer follow-up and prospective comparison are needed to verify these results.

引用

页码：2350 / 2356

页数：7

共 35 条

[11]

Ghielmini M, 2013, ANN ONCOL, V24, P561, DOI [10.1093/annonc/mds517, 10.1093/annonc/mdr388]

[12] Rituximab in the treatment of non-Hodgkin's lymphoma - a critical evaluation of randomized controlled trials [J].

Griffin, Morag Meriel ;

Morley, Nick .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) :803-811

[13] Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy [J].

Guadagnolo, BA ;

Li, SG ;

Neuberg, D ;

Ng, A ;

Hua, L ;

Silver, B ;

Stevenson, MA ;

Mauch, P .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (03) :928-934

[14] High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas [J].

Haas, RLM ;

Poortmans, P ;

de Jong, D ;

Aleman, BMP ;

Dewit, LGH ;

Verheij, M ;

Hart, AAM ;

van Oers, MHJ ;

van der Hulst, M ;

Baars, JW ;

Bartelink, H .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2474-2480

[15] CLINICAL STAGE-1 NON-HODGKINS-LYMPHOMA - LONG-TERM FOLLOW-UP OF PATIENTS TREATED BY THE BRITISH NATIONAL LYMPHOMA INVESTIGATION WITH RADIOTHERAPY ALONE AS INITIAL THERAPY [J].

HUDSON, BV ;

HUDSON, GV ;

MACLENNAN, KA ;

ANDERSON, L ;

LINCH, DC .

BRITISH JOURNAL OF CANCER, 1994, 69 (06) :1088-1093

[16] Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma:: The end of a dilemma? [J].

Janikova, Andrea ;

Bolcak, Karol ;

Pavlik, Tomas ;

Mayer, Jiri ;

Kral, Zdenek .

CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (05) :287-293

[17] A real-time (PCR) for a real life ...? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice [J].

Janikova, Andrea ;

Mareckova, Andrea ;

Dvorakova, Dana ;

Bortlicek, Zbynek ;

Tichy, Boris ;

Navratil, Milan ;

Kral, Zdenek ;

Pospisilova, Sarka ;

Mayer, Jiri .

EXPERIMENTAL HEMATOLOGY, 2012, 40 (07) :528-539

[18] A BRITISH-NATIONAL-LYMPHOMA-INVESTIGATION RANDOMIZED TRIAL OF SINGLE-AGENT CHLORAMBUCIL PLUS RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN LOW-GRADE, LOCALIZED NON-HODGKINS-LYMPHOMA [J].

KELSEY, SM ;

NEWLAND, AC ;

HUDSON, GV ;

JELLIFFE, AM .

MEDICAL ONCOLOGY, 1994, 11 (01) :19-25

[19] Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial [J].

Lowry, Lisa ;

Smith, Paul ;

Qian, Wendi ;

Falk, Stephen ;

Benstead, Kim ;

Illidge, Tim ;

Linch, David ;

Robinson, Martin ;

Jack, Andrew ;

Hoskin, Peter .

RADIOTHERAPY AND ONCOLOGY, 2011, 100 (01) :86-92

[20] Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University [J].

MacManus, MP ;

Hoppe, RT .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1282-1290

← 1 2 3 4 →